¹ Peterse I, Swartz L. Primary health care in the era of HIV/AIDS. Some implications for health systems reform. Soc Sci Med 2002;55:1005–13.

² Akinsola HA. Fostering hope in people living with AIDS in Africa: the role of primary health-care workers. Aust J Rural Health 2001;9:158–65.

³ Diarra A. Making a public-private partnership work—an insider’s view. Bull World Health Organ 2001;79:795–6.

⁴ Roeloffs C, Sherbourne C, Unutzer J, et al. Stigma and depression among primary care patients. Gen Hosp Psychiatry 2003;25:311–5.

⁵ Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS 2000;14:2159–69.

⁶ Harris SK, Samples CL, Keenan PM, et al. Outreach, mental health, and case management services: can they help to retain HIV-positive and at-risk youth and young adults in care? Matern Child Health J 2003;7:205–18.

⁷ Sivaram S, Celentano DD. Training outreach workers for AIDS prevention in rural India: is it sustainable? Health Policy Plan 2003;18:411–20.

⁸ DeRiemer K, Soares EC, Dias SM, Cavalcante SC. HIV testing among tuberculosis patients in the era of antiretroviral therapy: a population-based study in Brazil. Int J Tuberc Lung Dis 2000;4:519–27.

⁹ Banerjee A, Moyo S, Salaniponi F, Harries A. HIV testing and tuberculosis treatment outcome in a rural district in Malawi. Trans R Soc Trop Med Hyg 1997;91:707–8.

¹⁰ Tay EG, Emmanuel SC. Improving the uptake of human immunodeficiency virus (HIV) antenatal screening in a primary healthcare setting. Ann Acad Med Singapore 2003;32:92–5.

¹¹ Segurado AC, Miranda SD, Latorre MD, Brazilian Enhancing Care Initiative Team. Evaluation of the care of women living with HIV/AIDS in São Paulo, Brazil. AIDS Patient Care STDs 2003;17:85–93.

¹² Kahn RH, Moseley KE, Thilges JN, et al. Community-based screening and treatment for STDs: results from a mobile clinic initiative. Sex Transm Dis 2003;30:654–8.

¹³ Weinstock H, Dale M, Gwinn M, et al. HIV seroincidence among patients at clinics for sexually transmitted diseases in nine cities in the United States. J Acquir Immune Defic Syndr 2002;29:478–83.

¹⁴ Day S, Lakhani D, Rodgers C. Uptake of HIV testing in patients with a confirmed sexually transmitted infection. Sex Transm Infect 2002;78:389–90.

¹⁵ Coovadia HM. Access to voluntary counseling and testing for HIV in developing countries. Ann NY Acad Sci 2000;918:57–63.

¹⁶ World Health Organization. Rapid HIV tests: guidelines for use in HIV testing and counseling services in resource-constrained settings. Geneva: World Health Organization, 2004.

¹⁷ Anonymous. HIV testing: a practical approach. Trop Doct 2001;31:122.

¹⁸ Wilkinson D, Wilkinson N, Lombard C, et al. On-site HIV testing in resource-poor settings: is one rapid test enough? AIDS 1997;11:377–81.

¹⁹ Colebunders R, Beelaert G, Wellens R. HIV testing in developing countries [letter]. Lancet 1997;349:1258.

²⁰ Allen S, Meinzen-Derr J, Kautzman M, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 2003;17:733–40.

²¹ Davis K, Weller S. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272–9.

²² VanDevanter N, Thacker AS, Bass G, Arnold M. Heterosexual couples confronting the challenges of HIV infection. AIDS Care 1999;11:181–93.

²³ Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149–53.

²⁴ Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921–9.

²⁵ Cohen MS. Preventing sexual transmission of HIV: new ideas from sub-Saharan Africa. N Engl J Med 2000;342:970–2.

²⁶ Royce RA, Sena A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997;336:1072–8.

²⁷ Cameron DW, Simonsen JN, D’Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989;2:403–7.

²⁸ Mayer KH, Anderson DJ. Heterosexual HIV transmission. Infect Agents Dis 1995;4:273–84.

²⁹ Nicolosi A, Leite MLC, Musicco M, et al. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 1994;5:570–5.

³⁰ Hopewell PC, Chaisson RE. Tuberculosis and human immunodeficiency virus infection. In: Reichman LB, Hershfield ES, eds. Tuberculosis: a comprehensive international approach. 2nd ed. New York: Marcel Dekker, 2000:525–52.

³¹ Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545–50.

³² Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993;7:1345–9.

³³ Dutt AK, Stead WW. Epidemiology and host factors. In: Schlossberg D, ed. Tuberculosis and non-tuberculous mycobacterial infections. Philadelphia, PA: W.B. Saunders, 1999:3–16.

³⁴ Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137–44.

³⁵ Lienhardt C, Rodriques LC. Estimation of the impact of the human immunodeficiency virus infection on tuberculosis: tuberculosis risks revisited? Int J Tuberc Lung Dis 1997;1:196–204.

³⁶ Ellis BA, Crawford JT, Braden CR, et al. Molecular epidemiology of tuberculosis in a sentinel surveillance population. Emerg Infect Dis 2002;8:1197–209.

³⁷ Lourenco MC, Grinsztejn B, Fandinho-Montes FC, et al. Genotypic patterns of multiple isolates of M. tuberculosis from tuberculous HIV patients. Trop Med Int Health 2000;5:488–94.

³⁸ Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d’Ivoire. Lancet 1995;345:607–10.

³⁹ Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993;342:332–7.

⁴⁰ Pulido F, Pena JM, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997;157:227–32.

⁴¹ El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998;26:1148–58.

⁴² Badri M, Ehrlich R, Wood R, et al. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001;5:225–32.

⁴³ Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687–93.

⁴⁴ Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129–35.

⁴⁵ Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002;16:75–83.

⁴⁶ American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculosis testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221.

⁴⁷ Conde MB, Soares SL, Mello FC, et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil. Am J Respir Crit Care Med 2000;162:2238–54.

⁴⁸ Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1997;25:242–6.

⁴⁹ Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993;96:1–11

⁵⁰ Modilevsky T, Sattler FR, Barnes PF. Mycobacterial disease in patients with human immunodeficiency virus infection. Arch Intern Med 1989;149:2201–5.

⁵¹ Perriens JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779–84.

⁵² World Health Organization. Treatment of tuberculosis: guidelines for national programs. 3rd ed. Geneva: World Health Organization, 2003.

⁵³ Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006;43:253–5.

⁵⁴ Presentation by Donald Enarson on the preliminary results of Study A by the International Union Against Tuberculosis and Lung Disease, Scientific Task Force Meeting, 14 April 2004, World Health Organization, Geneva.

⁵⁵ American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–62.

⁵⁶ World Health Organization. Treatment of tuberculosis: guidelines for national programs. 3rd ed. Geneva: World Health Organization, 2003.

⁵⁷ De Lange WC. Immune reactivation and paradoxical worsening in an HIV-infected tuberculosis patient. Adv Exp Med Biol 2003;531:261–6.

⁵⁸ World Health Organization. Treatment of tuberculosis: guidelines for national programs. 3rd ed. Geneva: World Health Organization, 2003.

⁵⁹ Soriano E, Mallolas J, Gatell JM, et al. Characteristics of tuberculosis in HIV-infected patients: a case-control study. AIDS 1988;2:429–32.

⁶⁰ Breen RA, Lipman MC, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. AIDS 2000;14:615.

⁶¹ Figg DW. Peripheral neuropathy in HIV patients after isoniazid therapy initiated. Ann Pharmacother 1991;25:100–1.

⁶² Watkins WM, Mungai M, Muhia DK, et al. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma. Br J Clin Pharmacol 1996;41:160–2.

⁶³ Farmer PE. Social scientists and the new tuberculosis. Soc Sci Med 1997;44:347–58.

⁶⁴ Farmer P, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and “compliance”: lessons from rural Haiti. Sem Resp Infect 1991;6:254–60.

⁶⁵ Farmer P. Infections and inequalities: the modern plagues. Berkeley, CA: University of California Press, 1998.

⁶⁶ Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514–21.

⁶⁷ Gordin FM, Nelson ET, Matts JP, et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med 1996;154:1478–83.

⁶⁸ Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521–6.

⁶⁹ World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2006.

⁷⁰ Partners In Health; Program in Infectious Disease and Social Change, Harvard Medical School; Division of Social Medicine and Health Inequalities, Brigham and Women’s Hospital. The PIH guide to the medical management of multi-drug-resistant tuberculosis. International ed. Boston: Partners In Health, 2003.

⁷¹ Maher D, Floyd K, Raviglione M. A strategic framework to decrease the burden of TB/HIV. Geneva: World Health Organization, 2002.

⁷² Joint United Nations Program on HIV/AIDS, World Health Organization. AIDS epidemic update: December 2004. Geneva: World Health Organization, 2004.

⁷³ UNAIDS. 2004 report on the global HIV/AIDS epidemic. Geneva: Joint United Nations Program on HIV/AIDS. July 2004.

⁷⁴ Magalhaes J, Amaral E, Giraldo PC, Simoes JA. HIV infection in women: impact on contraception. Contraception 2002;66:87–91.

⁷⁵ Mitchell HS, Stephens E. Contraception choices for HIV positive women. Sex Transm Infect 2004;80:167–73.

⁷⁶ Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 2002;29:471–7.

⁷⁷ Fawzi WW, Msamanga GI, Spiegelman D, et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 1998;351:1477–82.

⁷⁸ Fawzi WW, Msamanga GI, Hunter D, et al. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS 2002;16:1935–44.

⁷⁹ Tovo P, Gabiano C, Tulisso S. Maternal clinical factors influencing HIV-1 transmission. Acta Paediatr Suppl 1997;421:52–5.

⁸⁰ Bobat R, Coovadia H, Coutsoudis A, et al. Determinants of mother-to-child transmission of human immunodeficiency virus type 1 infection in a cohort from Durban, South Africa. Pediatr Infect Dis J 1996;15:604–10.

⁸¹ Coll O, Hernandez M, Boucher C, et al. Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. J Acquir Immune Defic Syndr 1997;14:26–30.

⁸² Pitt J, Brambilla D, Reichelderfer P, et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis 1997;175:567–75.

⁸³ The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies. AIDS 2001;15:357–68.

⁸⁴ Mofenson L. A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus. Pediatr Infect Dis J 1995;14:169–176.

⁸⁵ Wabwire-Mangen F, Gray R, Mmiro F, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr 1999;22:379–85.

⁸⁶ Ioannidis JP, Abrams EJ, Ammann A. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001;183:539–45.

⁸⁷ Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999;341:394–402.

⁸⁸ Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States, 2005. (Accessed June 30, 2006, at: http://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search =Off&GuidelineID=9&ClassID=2.)

⁸⁹ Connor EM, Sperling RS, Gelber R. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173–80.

⁹⁰ Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 2005;19:1865–75.

⁹¹ Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725–35.

⁹² Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859–68.

⁹³ Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda: a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:1178–86.

⁹⁴ Chaisilwattana P, Chokephaibulkit K, Chalermchockcharoenkit A, et al. Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 2002;35:1405–13.

⁹⁵ Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. Lancet 1999;353:786–92.

⁹⁶ Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet 1999;353:781–5.

⁹⁷ Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353:773–80.

⁹⁸ Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795–802.

⁹⁹ Dabis, F, Ekouevi DK, Bequet L, et al. A short course of zidovudine and peripartum nevirapine is highly efficacious in preventing mother-to-child transmission of HIV-1: ARNS 1201 DITRAME-Plus study. In: Programs and abstracts of the 10th annual Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retroviruses and Human Health, 2003:120. (Accessed June 30, 2006 at: http://www.retroconference.org/2003/cd/Abstract/854.htm.)

¹⁰⁰ Lallemant M, Jourdain G, Le Coeur S, et al. Multicenter randomized controlled trial assessing the safety and efficacy of nevirapine in addition to zidovudine for the prevention of perinatal HIV in Thailand, PHPT-2 update. Antiviral Therapy 2003;8:S199.

¹⁰¹ Dabis F, Ekouevi D, Rouet F, et al. Effectiveness of a short course of zidovudine and lamivudine and peripartum nevirapine to prevent HIV-1 mother-to-child transmission. The ANRS DITRAME Plus trial, Abidjan, Côte d’Ivoire. Antiviral Therapy 2003;8:S236–7.

¹⁰² European Collaborative Study. HIV infected pregnant women vertical transmission in Europe since 1986. AIDS 2001;15:761–70.

¹⁰³ Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484–94.

¹⁰⁴ Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 U.S. women (PACTG 367). In: Programs and abstracts of the 11th annual Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retroviruses and Human Health, 2004. (Accessed June 30, 2006 at: http://www.retroconference.org/2004/cd/Abstract/99.htm.)

¹⁰⁵ Eshleman S, Mracna M, Guay L, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951–7.

¹⁰⁶ Eshleman SH, Cunningham SP, Jones D, et al. Analysis of nevirapine resistance seven days after single-dose nevirapine prophylaxis: HIVNET 012. In: Programs and abstracts of the 10th annual Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retroviruses and Human Health, 2003. (Accessed July 10, 2006 at: http://www.retroconference.org/2003/cd/Abstract/856.htm.)

¹⁰⁷ Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005;38:87–95.

¹⁰⁸ Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795–802.

¹⁰⁹ Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trail. JAMA 2004;292:202–9.

¹¹⁰ Toni TD, Masquelier B, Lazaro E, et al. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d’Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res Hum Retroviruses 2005;21:1031–4.

¹¹¹ Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy: a focus on safety. Drug Saf 2001;24:683–702.

¹¹² Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16:299–300.

¹¹³ De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects [letter]. Arch Intern Med 2002;162:355.

¹¹⁴ Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1002. J Acquir Immune Defic Syndr 2004;36:772–6.

¹¹⁵ Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34:S21–33.

¹¹⁶ Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatoxicity associated with nevirapine use in HIV-infected subjects. J Infect Disease 2005;191:825–9.

¹¹⁷ Joy S, Poi M, Hughes L, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol 2005;106:1032–8.

¹¹⁸ Custódio João E, Calvet GA, Menezes JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol 2005;194:199–202.

¹¹⁹ Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevaripine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351:217–28.

¹²⁰ Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723–30.

¹²¹ Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet 1999;353:901–2.

¹²² Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Inf 2002;78:58–9.

¹²³ Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002;29:207–20.

¹²⁴ The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1—a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977–87.

¹²⁵ The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353:1035–9.

¹²⁶ Shapiro D, Tuomala R, Samelson R, et al. Mother-to-child HIV transmission rates according to antiretroviral therapy, mode of delivery, and viral load (PACTG 367). In: Programs and abstracts of the 9th annual Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002. (Accessed June 30, 2006 at: http://www. retroconference.org/2002/Abstract/12953.htm.)

¹²⁷ Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after cesarean section in 156 HIV-positive women. AIDS 1995;9:913–7.

¹²⁸ Grubert TA, Reindell D, Kastner R, et al. Complications after caesarean section in HIV-1 infected women not taking antiretroviral treatment. Lancet 1999;354:1612–3.

¹²⁹ Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission through breastfeeding: a study in Malawi. JAMA 1999;282:744–9.

¹³⁰ Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr 2002;30:230–9.

¹³¹ Centers for Disease Control. Recommendations for assisting in the prevention of perinatal transmission of human T lymphotrophic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. MMWR 1985;34:731-2.

¹³² Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda: a randomised, double-blind, placebo-controlled trial. Lancet 2002;359:1178–86.

¹³³ Coutsoudis A, Pillay K, Spooner E, et al. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. Lancet 1999;354:471–6.

¹³⁴ Coutsoudis A, Pillay K, Kuhn L, et al. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001;15:379–87.

¹³⁵ Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999;180:93–8.

¹³⁶ Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000;283:1167–74.

¹³⁷ Fawzi W, Msamanga G, Spiegelman D, et al. Transmission of HIV-1 through breastfeeding among women in Dar es Salaam, Tanzania. J Acquir Immun Defic Syndr 2002;31:331–8.

¹³⁸ Fawzi WW, Msamanga GI, Hunter D, et al. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS 2002;16:1935–44.

¹³⁹ Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859–68.

¹⁴⁰ World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates 2001. Geneva: World Health Organization, 2001. (Accessed June 30, 2006 at: http://www.who.int/docstore/hiv/GRSTI/who_hiv_ aids_2001.02.pdf)

¹⁴¹ Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997;349:1868–73.

¹⁴² Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d’Ivoire. AIDS 1997;11:F85–93.

¹⁴³ Ministère de la Santé Publique et de la Population, Les Centres GHESKIO, OPS/OMS, avec la participation des Centres pour le Développement et la Santé, Save the Children, et la Coalition des ONG du Plateau Central. Prise en charge des maladies sexuellment transmissibles: protocoles pour les soins de santé primaires, 1998.

¹⁴⁴ World Health Organization. Guidelines for the management of sexually transmitted diseases 2003. Geneva: World Health Organization, 2003. (Accessed July 10, 2006 at: http://www.who.int/reproductive-health/publications/rhr_01_10_mngt_stis)

¹⁴⁵ Smith Fawzi MC, Lambert W, Singler J, et al. Identification of chlamydia and gonorrhea among women in rural Haiti: maximizing access to treatment in a resource-poor setting. Sex Transm Infect 2006;82:175–81.

¹⁴⁶ Mayaud P, Uledi E, Cornelissen J, et al. Risk scores to detect cervical infections in urban antenatal clinic attenders in Mwanza, Tanzania. Sex Transm Infect 1998;74:S139–46.

¹⁴⁷ Kiss H, Petricevic L, Husslein P. Prospective randomized controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004;329:371–4.